

A palladium-catalyzed reaction of aryl halides, potassium metabisulfite, and hydrazines

Shengqing Ye,[†] and Jie Wu^{*,†,‡}

[†] Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China [‡]

State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry,
Chinese Academy of Sciences, Shanghai 200032, China

jie_wu@fudan.edu.cn


Supporting Information

1. General experimental methods (S2).
2. General experimental procedure and characterization data (S2-S9).
3. ¹H and ¹³C NMR spectra of compound **3** (S10-S55).

General experimental methods:


Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32–63 µm, standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25–35°C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument.

*General experimental procedure for the palladium-catalyzed three-component reaction of aryl iodide **1**, potassium metabisulfite, with hydrazines **2***




Hydrazine **2** (0.6 mmol) was added to a mixture of aryl iodide **1** (0.5 mmol), potassium metabisulfite (0.5 mmol), $\text{Pd}(\text{OAc})_2$ (5 mol %), $\text{P}^t\text{Bu}_3 \cdot \text{HBF}_4$ (10 mol %), HBF_4 (20 mol %), and TBAB (0.75 mmol) in 1,4-dioxane (2.0 mL). The reaction was stirred at 80 °C for 12 hours. After completion of the reaction as indicated by TLC, the residue was purified directly by flash chromatography on silica gel to afford aryl *N*-aminosulfonamides **3**.

*General experimental procedure for the palladium-catalyzed three-component reaction of aryl bromide **4**, potassium metabisulfite, with hydrazines **2***




Hydrazine **2** (0.75 mmol) was added to a mixture of aryl bromide **4** (0.5 mmol), potassium metabisulfite (1.0 mmol), Pd(OAc)₂ (10 mol %), P'Bu₃-HBF₄ (30 mol %) and TBAB (0.75 mmol) in 1,4-dioxane (2.0 mL). The reaction was stirred at 100 °C for 12 hours. After completion of the reaction as indicated by TLC, the residue was purified directly by flash chromatography on silica gel to afford aryl *N*-aminosulfonamides **3**.




4-Methyl-*N*-morpholinobenzenesulfonamide (**3a**)¹

¹H NMR (400 MHz, CDCl₃) δ 2.43 (s, 3H), 2.63 (t, *J* = 4.1 Hz, 4H), 3.59 (d, *J* = 4.4 Hz, 4H), 6.21 (s, 1H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.86 (d, *J* = 8.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.4, 56.3, 66.5, 128.0, 129.3, 135.5, 143.8.



2-Methyl-*N*-morpholinobenzenesulfonamide (**3b**)¹


¹H NMR (400 MHz, CDCl₃) δ 2.65 (t, *J* = 4.6 Hz, 4H), 2.70 (s, 3H), 3.57 (t, *J* = 4.1 Hz, 4H), 5.98 (s, 1H), 7.29-7.35 (m, 2H), 7.47 (t, *J* = 7.8 Hz, 1H), 8.07 (d, *J* = 7.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.6, 56.5, 66.5, 126.0, 130.9, 132.2, 133.1, 136.4, 137.9.



4-Methoxy-*N*-morpholinobenzenesulfonamide (**3c**)¹


¹H NMR (400 MHz, CDCl₃) δ 2.62 (t, *J* = 4.6 Hz, 4H), 3.61 (t, *J* = 4.1 Hz, 4H), 3.88 (s, 3H), 5.68 (s, 1H), 6.98 (d, *J* = 9.2 Hz, 2H), 7.90 (d, *J* = 9.2 Hz, 2H); ¹³C NMR

(100 MHz, CDCl₃) δ 55.6, 56.6, 66.6, 113.9, 130.0, 130.3, 163.2.




2-Methoxy-*N*-morpholinobenzenesulfonamide (**3d**)¹

¹H NMR (400 MHz, CDCl₃) δ 2.67 (t, *J* = 4.6 Hz, 4H), 3.56 (t, *J* = 4.1 Hz, 4H), 4.00 (s, 3H), 6.19 (s, 1H), 7.04 (d, *J* = 8.2 Hz, 1H), 7.10 (t, *J* = 7.8 Hz, 1H), 7.58 (t, *J* = 7.3 Hz, 1H), 8.00 (d, *J* = 7.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 56.2, 56.3, 66.3, 112.0, 120.6, 126.7, 131.7, 135.0, 156.1.




3-Methoxy-*N*-morpholinobenzenesulfonamide (**3e**)¹

¹H NMR (400 MHz, CDCl₃) δ 2.64 (t, *J* = 4.1 Hz, 4H), 3.60 (d, *J* = 4.1 Hz, 4H), 3.86 (s, 3H), 6.19 (s, 1H), 7.13 (d, *J* = 7.8 Hz, 1H), 7.42 (t, *J* = 8.2 Hz, 1H), 7.50 (s, 1H), 7.56 (d, *J* = 7.3 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 55.6, 56.4, 66.5, 112.5, 119.5, 120.1, 129.8, 139.7, 159.6.



4-(*tert*-Butyl)-*N*-morpholinobenzenesulfonamide (**3f**)¹


¹H NMR (400 MHz, CDCl₃) δ 1.34 (s, 9H), 2.64 (s, 4H), 3.61 (s, 4H), 6.25 (s, 1H), 7.53 (d, *J* = 8.3 Hz, 2H), 7.90 (d, *J* = 8.3 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 30.9, 35.0, 56.4, 66.4, 125.6, 127.8, 135.5, 156.8.



N-Morpholino-[1,1'-biphenyl]-4-sulfonamide (**3g**)¹


¹H NMR (400 MHz, CDCl₃) δ 2.67 (t, *J* = 4.6 Hz, 4H), 3.62 (t, *J* = 4.6 Hz, 4H), 5.89 (s, 1H), 7.40-7.50 (m, 3H), 7.62 (d, *J* = 7.3 Hz, 2H), 7.74 (d, *J* = 7.8 Hz, 2H), 8.04 (d,

$J = 8.2$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 56.7, 66.6, 127.2, 127.3, 128.5, 128.6, 129.0, 137.2, 139.0, 145.9.




4-Hydroxy-*N*-morpholinobenzenesulfonamide (3h**)¹**

^1H NMR (400 MHz, CD_3OD) δ 2.55 (t, $J = 4.56$, 4H), 3.55 (t, $J = 4.1$ Hz, 4H), 4.88 (br, 2H), 6.91 (d, $J = 8.7$ Hz, 2H), 7.76 (d, $J = 8.7$ Hz, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ 56.0, 66.5, 115.1, 129.1, 130.1, 161.9.




4-Amino-*N*-morpholinobenzenesulfonamide (3i**)²**

^1H NMR (400 MHz, CD_3OD) δ 2.55 (t, $J = 4.6$ Hz, 4H), 3.55 (t, $J = 4.2$ Hz, 4H), 4.83 (s, 3H), 6.69 (d, $J = 8.2$ Hz, 2H), 7.58 (d, $J = 8.2$ Hz, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ 56.0, 66.5, 112.8, 124.6, 129.8, 153.2.




4-(Hydroxymethyl)-*N*-morpholinobenzenesulfonamide (3j**)**

^1H NMR (400 MHz, CD_3OD) δ 2.55 (t, $J = 4.6$ Hz, 4H), 3.53 (d, $J = 4.1$ Hz, 4H), 4.69 (s, 2H), 4.86 (s, 2H), 7.55 (d, $J = 7.8$ Hz, 2H), 7.90 (d, $J = 7.8$ Hz, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ 56.0, 62.9, 66.4, 126.5, 127.9, 138.0, 147.3. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{16}\text{N}_2\text{NaO}_4\text{S}$: 295.0723 ($\text{M} + \text{Na}^+$), found: 295.0712.




***N*-Morpholinobenzenesulfonamide (**3k**)¹**


^1H NMR (400 MHz, CDCl_3) δ 2.62 (t, $J = 4.1$ Hz, 4H), 3.59 (t, $J = 4.1$ Hz, 4H), 6.11 (s, 1H), 7.53 (t, $J = 7.3$ Hz, 2H), 7.61 (t, $J = 7.3$ Hz, 1H), 7.98 (d, $J = 7.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 56.4, 66.5, 128.0, 128.7, 133.0, 138.5.




¹H NMR (400 MHz, CDCl₃) δ 2.53 (t, *J* = 4.6 Hz, 4H), 3.46 (t, *J* = 4.1 Hz, 4H), 6.12 (s, 1H), 7.54-7.60 (m, 2H), 7.66 (t, *J* = 7.3 Hz, 1H), 7.92 (d, *J* = 8.2 Hz, 1H), 8.08 (d, *J* = 7.8 Hz, 1H), 8.39 (d, *J* = 7.3 Hz, 1H), 8.81 (d, *J* = 8.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 56.6, 66.4, 124.1, 125.0, 126.7, 128.1, 128.4, 128.8, 131.3, 133.5, 133.9, 134.7.



¹H NMR (400 MHz, CDCl₃) δ 2.64 (t, *J* = 4.6 Hz, 4H), 3.62 (t, *J* = 4.6 Hz, 4H), 5.57 (s, 1H), 7.21 (t, *J* = 8.7 Hz, 2H), 8.00 (dd, *J* = 5.0, 8.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 56.7, 66.6, 116.1 (d, *J_{CF}* = 22.9 Hz), 130.9 (d, *J_{CF}* = 9.5 Hz), 134.6, 165.4 (d, *J_{CF}* = 254.6 Hz).




¹H NMR (400 MHz, CDCl₃) δ 2.65 (t, *J* = 4.6 Hz, 4H), 3.62 (t, *J* = 4.1 Hz, 4H), 5.74 (s, 1H), 7.51 (d, *J* = 8.7 Hz, 2H), 7.91 (d, *J* = 8.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 56.6, 66.6, 129.1, 129.6, 137.0, 139.7.




¹H NMR (400 MHz, CDCl₃) δ 2.65 (t, *J* = 4.6 Hz, 4H), 3.61 (t, *J* = 4.6 Hz, 4H), 5.99 (s, 1H), 7.67 (d, *J* = 8.7 Hz, 2H), 7.84 (d, *J* = 8.3 Hz, 2H); ¹³C NMR (100 MHz,

CDCl_3) δ 56.5, 66.5, 128.2, 129.6, 132.1, 137.6.




Ethyl 4-(*N*-morpholinosulfamoyl)benzoate (**3p**)

^1H NMR (400 MHz, CDCl_3) δ 1.43 (t, $J = 7.3$ Hz, 3H), 2.66 (s, 4H), 3.61 (s, 4H), 4.43 (q, $J = 6.8$ Hz, 2H), 6.14 (s, 1H), 8.06 (d, $J = 7.8$ Hz, 2H), 8.19 (d, $J = 7.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.2, 56.5, 61.7, 66.5, 128.0, 129.9, 134.5, 142.4, 165.1. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{NaO}_5\text{S}$: 337.0829 ($\text{M} + \text{Na}^+$), found: 337.0846.




N-Morpholino-4-(trifluoromethyl)benzenesulfonamide (**3q**)¹

^1H NMR (400 MHz, CDCl_3) δ 2.67 (s, 4H), 3.63 (s, 4H), 5.86 (s, 1H), 7.80 (d, $J = 7.8$ Hz, 2H), 8.12 (d, $J = 7.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 56.7, 66.5, 123.1 (q, $J_{CF} = 271.7$ Hz), 125.9 (d, $J_{CF} = 3.8$ Hz), 128.6, 134.8 (q, $J_{CF} = 32.4$ Hz), 142.2.



N-Morpholino-4-(trifluoromethoxy)benzenesulfonamide (**3r**)


^1H NMR (400 MHz, CDCl_3) δ 2.66 (s, 4H), 3.62 (s, 4H), 6.07 (s, 1H), 7.36 (d, $J = 8.2$ Hz, 2H), 8.04 (d, $J = 8.7$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 56.6, 66.5, 120.1 (d, $J_{CF} = 257.4$ Hz), 120.5, 130.3, 136.8, 152.4. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_4\text{S}$: 327.0621 ($\text{M} + \text{H}^+$), found: 327.0623.



4-Methyl-*N*-(piperidin-1-yl)benzenesulfonamide (**3s**)¹


^1H NMR (400 MHz, CDCl_3) δ 1.28 (s, 2H), 1.46-1.50 (m, 4H), 2.43 (s, 3H), 2.52-2.54 (m, 4H), 5.77 (s, 1H), 7.30 (d, $J = 7.8$ Hz, 2H), 7.85 (d, $J = 8.2$ Hz, 2H); ^{13}C NMR

(100 MHz, CDCl₃) δ 21.5, 22.9, 25.5, 57.5, 128.0, 129.2, 135.8, 143.5.




4-Methoxy-N'-methyl-N'-phenylbenzenesulfonohydrazide (3t)³

¹H NMR (400 MHz, CDCl₃) δ 2.9 (s, 3H), 3.8 (s, 3H), 6.42 (s, 1H), 6.82-6.87 (m, 3H), 6.92 (d, *J* = 8.7 Hz, 2H), 7.15 (t, *J* = 8.2 Hz, 2H), 7.85 (d, *J* = 8.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 42.4, 55.5, 114.2, 114.3, 120.7, 128.8, 129.4, 129.9, 130.3, 149.8, 163.3.




4-Methoxy-N-(piperidin-1-yl)benzenesulfonamide (3u)³

¹H NMR (400 MHz, CDCl₃) δ 1.26-1.29 (m, 2H), 1.46-1.51 (m, 4H), 2.52-2.53 (m, 4H), 3.87 (s, 3H), 5.58 (s, 1H), 6.97 (d, *J* = 8.7 Hz, 2H), 7.89 (d, *J* = 8.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 22.9, 25.6, 55.5, 57.6, 113.7, 130.2, 130.3, 163.0.



4-(Cyanomethyl)-N-morpholinobenzenesulfonamide (3v)

¹H NMR (400 MHz, DMSO-*d*₆) δ 3.00 (t, *J* = 4.1 Hz, 4H), 3.96 (s, 4H), 4.70 (s, 2H), 8.09 (d, *J* = 7.8 Hz, 2H), 8.40 (d, *J* = 8.2 Hz, 2H), 9.45 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 22.9, 56.3, 66.4, 119.1, 128.6, 129.1, 136.9, 139.4. HRMS (ESI) calcd for C₁₂H₁₅N₃NaO₃S: 304.0726 (M + Na⁺), found: 304.0728.



6-Hydroxy-N-morpholinonaphthalene-2-sulfonamide (3w)

¹H NMR (400 MHz, CD₃OD) δ 2.55 (t, *J* = 4.6 Hz, 4H), 3.50 (t, *J* = 4.1 Hz, 4H), 4.88 (br, 2H), 7.20-7.23 (m, 2H), 7.77-7.80 (m, 2H), 7.90 (d, *J* = 8.2 Hz, 1H), 8.38 (s, 1H);

¹³C NMR (100 MHz, CD₃OD) δ 56.1, 66.4, 108.8, 119.8, 123.3, 126.7, 126.8, 129.2, 130.7, 132.9, 137.1, 158.2. HRMS (ESI) calcd for C₁₄H₁₆N₂NaO₄S: 331.0723 (M + Na⁺), found: 331.0705.

-
- [1] B. Nguyen, E. J. Emmett, M. C. Willis, *J. Am. Chem. Soc.* **2010**, *132*, 16372.
 - [2] E. J. Emmett, C. S. Richards-Taylor, B. Nguyen, A. Garcia-Rubia, B. R. Hayter, M. C. Willis, *Org. Biomol. Chem.* **2012**, *10*, 4007.
 - [3] S. Ye, J. Wu, *Chem. Commun.* **2012**, DOI:10.1039/C2CC33725H.

